This section provides an overview of the clinical features associated with selected bleeding disorders.
Alloantibody inhibitors to factor (F) VIII or FIX may develop in a subgroup of patients with haemophilia A (HA) or B (HB) and are a significant complication of haemophilia treatment. These inhibitors partially or completely neutralise the clotting activity of residual factor activity and render standard replacement therapy partially or completely ineffective.
Factor (F) XIII congenital deficiency (FXIII CD) is a rare autosomal recessive bleeding disorder that is the result of an impaired production of FXIII, the terminal enzyme in the blood coagulation cascade that stabilises the already formed blood clot during the haemostatic process.
Glanzmann’s thrombasthenia (GT) is a rare autosomal recessive platelet function disorder caused by a quantitative or qualitative defect in platelet membrane glycoprotein IIb/IIIa, which functions as a receptor for fibrinogen and is involved in platelet aggregation and fibrin clot retraction.